IBSA UK&I has announced the launch of Perovial, a treatment for the management of acute Peyronie’s disease (PD).
PD is a chronic, progressive condition caused by the formation of plaque in the tunica albuginea. Characteristic symptoms include penile curvature, deformity, pain and erectile dysfunction. It is estimated that between 0.3% and 13.1% of men worldwide live with PD, but underdiagnosis, symptom delay and embarrassment mean that the true number is likely to be higher.
Approximately 60% of men with Peyronie’s disease see the disease negatively impact their quality of life. Early recognition of symptoms is vital, since, once the disease reaches the acute phase, treatment options are limited. Intervention during the acute phase could, however, inhibit the progression of scarring and deformity from the disease.
Perovial is the first ever hyaluronic acid injectable treatment to be licensed in this indication. It is delivered via injection over 10-12 weeks of treatment, and the hyaluronic acid it contains is intended to soften plaque and encourage the remodelling of tissue.
Clinical trials of Perovial have demonstrated improvements in plaque size, penile curvature and erectile function, as well as a tolerable safety profile.
Professor David Ralph, professor of urology at University College London, St Peter’s Andrology and a UK urology andrologist, said: “PD is often misunderstood, underdiagnosed and undertreated, partly because many men delay seeking help and partly because clinicians have had limited options to offer during the acute phase.
“The availability of a licensed hyaluronic acid injectable such as Perovial provides a much-needed structured pathway for early intervention. Improving recognition of the acute phase and providing accessible treatment choices could make a significant difference to long-term outcomes for many patients.”
